Ocular Therapeutix, Inc.
NASDAQ: OCUL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Pravin U. Dugel
- Employees
- 274
- Headquarters
- Bedford, United States
- IPO year
- 2014
- Market cap
- $2.2B
- Website
- https://www.ocutx.com
Loading OCUL…
Loading profile data…Frequently asked questions about OCUL
What does Ocular Therapeutix, Inc. (OCUL) do?
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an...
Where does OCUL trade?
Ocular Therapeutix, Inc. (OCUL) trades on the NASDAQ Global Market.
What sector is OCUL in?
Ocular Therapeutix, Inc. (OCUL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ocular Therapeutix, Inc.?
Pravin U. Dugel is the chief executive officer of Ocular Therapeutix, Inc. (OCUL).
Where is Ocular Therapeutix, Inc. headquartered?
Ocular Therapeutix, Inc. is headquartered in United States.
Does OCUL pay a dividend?
Ocular Therapeutix, Inc. (OCUL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OCUL go public?
Ocular Therapeutix, Inc. (OCUL) completed its initial public offering in 2014.